Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data
In a meta-analysis using individual participant data, Jordan Cates and colleagues explore potential interactions between malaria and nutrition during pregnancy and their associations with low birthweight.
Published in the journal:
Malaria, malnutrition, and birthweight: A meta-analysis using individual participant data. PLoS Med 14(8): e32767. doi:10.1371/journal.pmed.1002373
Category:
Research Article
doi:
https://doi.org/10.1371/journal.pmed.1002373
Summary
In a meta-analysis using individual participant data, Jordan Cates and colleagues explore potential interactions between malaria and nutrition during pregnancy and their associations with low birthweight.
Introduction
Annually, over 20 million infants are born low birthweight (LBW; <2,500 g), predominantly in low- and middle-income countries (LMICs) [1]. LBW can have negative impacts on neonatal mortality and childhood neurological, metabolic, and physical development [2]. The World Health Organization (WHO) has set a Global Nutrition Target of 30% reduction in LBW by 2025 [1].
One preventable cause of LBW in LMICs is maternal malaria infection [2,3]. Its prevalence remains high, despite targeted malaria prevention programs [2]. Annually, 125 million pregnant women are at risk for malaria [4]. The predominant species, Plasmodium falciparum, sequesters in the placenta, causing LBW through fetal growth restriction (FGR) and preterm delivery [2]. Prior estimates from Africa suggest that malaria infection doubles the risk of LBW [2,4]. The prevention of malaria infection during pregnancy remains a public health priority.
Another modifiable risk factor for impaired fetal growth is maternal malnutrition, specifically undernutrition [5]. Up to 20% of African women of reproductive age are undernourished [5–7]. Maternal protein-energy-fat (macronutrient) and micronutrient reserves and dietary consumption influence fetal growth. Micronutrient deficiencies are difficult and costly to assess; therefore, anthropometrics are commonly used as sensitive but nonspecific indicators of protein reserves, fat stores, and malnutrition more broadly [7].
Recent evidence indicates that the relationship between malaria infection and LBW may depend upon the mother’s nutritional status [8]. Studies in Papua New Guinea (PNG) and Benin found inconsistent evidence of modification of the malaria infection–LBW relationship by maternal anthropometric status, but studies from Kenya and the Democratic Republic of the Congo (DRC) reported significant modification [9–12]. Notably, in the DRC, the risk of FGR associated with malaria infection was 2 to 8 times higher among malnourished women [11]. Malaria infection and malnutrition may act along similar physiological pathways by affecting placental development and nutrient transfer [2,4,5].
To date, work on this potential interaction has been limited to 4 studies, with only 1,318 pregnant women from Africa and 1,369 pregnant women from PNG. Not only were these studies somewhat inconsistent in their findings, but their interpretation is hindered by relatively small sample sizes, and their findings may not be generalizable to other malaria-endemic countries. The objective of this study was to investigate the putative interaction between maternal malaria infection and malnutrition in relation to birthweight (BW) using a large, pooled dataset of 14,633 live birth pregnancies from women participating in 13 studies conducted in multiple LMICs. We hypothesized that there would be a synergistic interaction, such that the observed joint effect of being both infected with malaria and malnourished would be greater than expected if considering each exposure independently.
Methods
Study population
We used data from 14,633 singleton live birth pregnancies from women participating in 13 studies conducted from 1996 to 2015 in 8 African countries and the Western Pacific (PNG) as part of the Maternal Malaria and Malnutrition (M3) initiative [9,11,13–24]. The M3 initiative has been described in detail previously [25]. Briefly, the M3 initiative is a collaboration with the Malaria in Pregnancy Consortium (MiPc) and affiliated malaria and nutrition researchers who agreed to pool resources to improve the understanding of malaria–nutrition interactions. A convenience sampling approach was taken to obtain eligible studies identified by researchers within the MiPc, and inclusion of studies for the individual participant data meta-analysis stopped 1 January 2016. Studies were eligible if they were an observational study or randomized controlled trial conducted between 1996 and 2015 enrolling pregnant women during pregnancy with follow-up through delivery and they met the following criteria: ethical approval allowed for secondary analyses and data sharing, malaria was endemic in the area with medium to high transmission, assessment of malariometric indices (light microscopy [LM] and/or rapid diagnostic tests [RDT]) at enrollment/first antenatal care visit (ANC), assessment of anthropometric indicators at enrollment (mid-upper arm circumference [MUAC] and/or body mass index [BMI]), and assessment of infant weight within 24 hours postpartum or within 7 days of birth if timing of weight measurement data was available. Data was shared by each individual study using a standardized data transfer file. Participating studies had been undertaken for a range of objectives, including investigation of the mechanisms leading to LBW as a result of malaria, evaluation of antimalarial interventions during pregnancy such as intermittent preventive therapy during pregnancy (IPTp) or insecticide-treated bed nets (ITN), or the assessment of the potential of nutritional supplementation during pregnancy to improve birth outcomes (S1 Table). All studies received approval by their local ethics board and obtained informed consent from all participants. The prospective protocol for the IPD analysis is included in the supplemental text (S2 Text).
Outcomes and exposures
The main outcome measure was BW, analyzed both continuously and dichotomized at 2,500 grams (LBW) [1]. Ten studies used digital scales to weigh newborns, 2 studies used spring or digital scales, and 1 study used a hanging weighing scale (S2 Table). Weights measured after 24 hours (13% of weights) were adjusted using a cubic regression model to account for weight changes in the first week of life [26]. Among 9 studies with ultrasound-dated gestational age, we considered 2 secondary outcomes: small for gestational age (SGA; a BW less than the 10th percentile of the INTERGROWTH-21st reference) and preterm birth (PTB; gestational age less than 37 weeks) [27].
Diagnostics for malaria were collected at study enrollment and at delivery. For the interaction analyses, we chose to focus on malaria infection at enrollment instead of at delivery for 2 reasons. First, from a public health perspective, if there was interaction at the time of study enrollment, this might help inform future interventions that could be implemented during antenatal care. Second, it has been hypothesized that malaria infection and malnutrition may act along similar physiological pathways to alter fetal growth by decreasing maternal–fetal oxygen transfer and reducing uteroplacental blood flow; 2 mechanisms that would be altered earlier in pregnancy versus at delivery. At study enrollment, we defined malaria based on LM examination of a Giemsa-stained peripheral blood smear or a RDT for malaria antigen [28]. At delivery, we defined malaria based on peripheral or placental LM or placental histology (active or past infection). Given the uncertain impact of submicroscopic infections on LBW and the variation in the availability of polymerase chain reaction (PCR) diagnostics across studies, we excluded PCR results [29]. In sensitivity analyses, we explored alternative definitions of malaria, including any PCR results and “any malaria,” defined as a positive LM, RDT, or PCR at enrollment, delivery, or during pregnancy (in 5 studies with repeat malaria diagnostics throughout pregnancy).
The primary measure of maternal malnutrition was low MUAC at enrollment, dichotomized at 23 cm [7]. MUAC changes little over pregnancy, making it a useful measure of malnutrition [7]. Since some studies did not measure MUAC, we used BMI as a secondary measure of malnutrition. According to WHO, a prepregnancy BMI <18.5 kg/m2 is predictive of adverse birth outcomes [30]. BMI at enrollment was used to estimate prepregnancy BMI by adjusting maternal weight measured in the second/third trimesters using a cubic regression model to account for gestational weight gain [30]. Low adjusted-BMI was defined as values under 18.5 kg/m2. As the correlation between BMI and MUAC is not perfect, indicators were analyzed separately [7]. The reason for dichotomizing MUAC and BMI was 2-fold. First, cutoffs are endorsed by WHO, are clinically easier to use, and are commonly used in the current literature to define undernutrition [7]. Second, while continuous exposures can be assessed in interaction models, interpretation is difficult, as the interaction estimates vary according to the levels of the exposures being compared and can vary in directionality as well [31].
Risk of bias assessment
We developed a checklist of study characteristics for each of the included individual studies to assess the risk of bias for the main evaluation of the interaction between malaria infection and maternal malnutrition on BW. Criteria were specific to the research question and were informed by the Newcastle-Ottawa Scale, Downs and Black instrument, and the Meta-Analysis of Observational Studies in Epidemiology checklist [32–34]. For each included study, we evaluated the individual study publications or contacted individual study collaborators to identify the following items to categorize studies as being either at lower or higher risk of bias: participant retention rate (<75% versus ≥75%), measurement of important confounders (maternal age, gravidity, rural versus urban residence, HIV infection, and anemia at enrollment), clearly described measurement of malaria parasitemia, measurement of MUAC and/or BMI, >80% of BWs measured using electronic scale with known precision ≤20 g, and >80% BWs measured within 24 hours. Studies were defined as at lower risk of bias if every item was determined to be at a lower risk of bias.
Statistical analysis
We analyzed maternal malaria infection and malnutrition as coprimary exposures and assessed malnutrition as a modifier of the malaria–LBW relationship. While effect measure modification (EMM) assesses how the effect of 1 exposure varies across strata of another variable, interaction analyses assess the joint effects of 2 exposures [35]. We performed both interaction and EMM analyses; however, in the context of this work, interaction is preferable to EMM because interventions for both malaria infection and malnutrition might prevent LBW.
There are 2 commonly employed approaches for handling individual pooled data, a 1-stage and a 2-stage approach, although there is no consensus as to which approach is preferable [36–38]. We employed a 2-stage approach, as it is generally considered more easily interpretable and allows the investigator to visually present forest plots and quantify statistical heterogeneity [36]. We examined the consistency of results with a 1-stage approach, fitting a generalized mixed model with random intercepts and slopes. Study-specific risk ratios (RRs) and mean BW differences were calculated using linear and log-binomial regression models controlling for confounding using inverse probability of treatment weights (IPTW) truncated at the 1st and 99th percentiles. A minimally sufficient set of confounders was identified using a directed acyclic graph based upon background knowledge of covariate relationships [39]. We identified confounders for both malaria infection and malnutrition relative to LBW since we were analyzing them as coprimary exposures. Confounders for the relationship between malaria infection at enrollment and LBW included maternal age, gravidity, rural versus urban residence, malnutrition (MUAC when available, otherwise BMI), and HIV infection. Because malaria infection is a cause of anemia, the latter was considered a mediator and not a confounder. We explored modification of the effect of malaria infection at enrollment on LBW by maternal gravidity and doses of intermittent preventive therapy (IPTp) received. When assessing malaria infection at delivery, anemia at enrollment and the number of IPTp doses were considered additional confounders. Confounders for the malnutrition–LBW relationship included maternal age, gravidity, rural versus urban residence, anemia at enrollment, and HIV infection. Partially missing data were imputed using multivariate normal multiple imputation (S1 Text) [40]. We calculated interaction estimates using a product term in the multiplicative and additive model for LBW and the additive model for mean BW [35]. These estimates reflect whether the effect of exposure to both malaria infection and malnutrition exceeds the product (or sum) of the effects of each exposure considered separately, defined as synergy. A product term greater than 1 on the multiplicative scale or greater than 0 on the additive scale is indicative of synergistic interaction between malaria infection and malnutrition.
Study-specific estimates were pooled using DerSimonian and Laird restricted maximum likelihood method random-effects models [41]. When τ2, the estimated variance of the random-effects distribution, was greater than 0, we calculated 95% population effects intervals (PEI), which incorporate the estimated variance between studies [41]. If τ2 equaled 0, the random-effects model was interpreted as a fixed-effects model. We decided a priori to evaluate the modification of the results by time period (before versus after 2008) due to changes in antimalarial recommendations, study type (trial/cohort), location (Africa/Western Pacific), and the study-level prevalence of malaria infection at study enrollment and delivery based on the individual study data, using meta-regression. We further decided post hoc to conduct a sensitivity analysis for the interaction analyses restricted to adolescent women.
Results
Using a convenience sample approach, a total of 18 studies were considered for inclusion by the time of our inclusion cutoff date (1 January 2016), of which 13 were included in the pooled analysis (Fig 1). We excluded 5 studies: 2 studies did not assess malaria at antenatal enrollment [42,43], 1 study had data that were not yet available for inclusion [44], 1 recruited women comparatively late in pregnancy [10], and 1 had not directly measured the number of sulfadoxine-pyrimethamine (SP) doses given for IPTp [45]. Following the cutoff date, 5 further studies were identified, of which 4 could be eligible with a collective sample size of 3,528 pregnant women (S3 Table) [46–50].
Study population characteristics
Twenty-five percent of the pooled dataset comprised adolescent women aged 19 or younger. The trimester at enrollment, anemia prevalence, gravidity distribution, area of residence, and HIV prevalence varied across studies (Tables 1 and 2). The prevalence of malaria infection at enrollment, malaria infection at delivery, low MUAC, and joint malaria infection at enrollment and low MUAC also varied by study (Fig 2 and S5 Fig). Among 8,152 women with both measurements, only 2% had both low MUAC and malaria infection at enrollment. The prevalence of malaria infection among women with low MUAC was 16%, compared to 12% among well-nourished women (p = 0.0005). The prevalence of low BMI varied across studies and was different from, although correlated with, the prevalence of low MUAC (χ2 p < 0.0001; S1 Fig). The joint prevalence of malaria infection at enrollment and low BMI was also 2%. Of all 14,633 women, 35% were infected with malaria at either enrollment or delivery or had low MUAC or BMI. The prevalence of LBW was 9% (range 5% to 15% among studies). Among 9 studies with ultrasound-dated gestational age, the prevalence of SGA was 19% (range 13% to 25%), and the prevalence of PTB was 11% (range 3% to 20%).
Five of the thirteen included studies were judged to be at a lower risk of bias for the assessment of interaction between malaria infection and maternal malnutrition on BW (S4 Table). Among the 8 other studies, 3 had a <75% retention rate for the primary outcome, 5 did not measure at least 80% of BWs with an electronic scale with known precision ≤20 g, and 3 did not measure at least 80% of BWs within 24 hours.
Independent effects of malaria infection and malnutrition
The pooled IPTW-adjusted risk ratio (aRR) for the effect of malaria infection at enrollment on LBW was 1.14 (95% CI: 0.91, 1.42; 95% τ2 = 0.05 [95% CI: 0.00, 0.25]; PEI: 0.72, 1.80), and the mean BW difference was −55 g (95% CI: −79, −30; τ2 = 0 [95% CI: 0.00, 1,610]) (Fig 3a). The effect of malaria infection at delivery was more pronounced: aRR, 1.32 (95% CI: 1.08, 1.62; τ2 = 0.04 [95% CI: 0.00, 0.39]; 95% PEI: 0.91, 1.91) (Fig 3b). When considering SGA and PTB as secondary outcomes, results were similar for malaria infection at enrollment and attenuated for malaria infection at delivery (S5 Table). The effect of malaria infection at enrollment was attenuated among those with more than 1 IPTp dose versus 1 or 0 doses (aRR 0.98 versus 1.22) and was slightly stronger among primi/secundigravid versus multigravida women (aRR 1.19 versus 1.14). A slightly stronger effect of malaria infection was seen among women enrolled in studies conducted prior to 2008, in Africa, or with malaria infection prevalence at or above the median (S2 Fig).
The aRR for the effect of low MUAC on LBW was 1.60 (95% CI: 1.36, 1.87; τ2 = 0 [95% CI: 0.00, 0.05]); the mean BW difference was −142 g (95% CI: −171, −113; τ2 = 0 [95% CI: 0, 100] (Fig 4a). Results were similar for low BMI: aRR, 1.49 (95% CI: 1.26, 1.76; τ2 = 0 [95% CI: 0.00, 0.16]); mean BW difference −133 g (95% CI: −158, −108; τ2 = 0 [95% CI: 0.00, 0.00]) (Fig 4b). There was no modification by study characteristics on the malnutrition–LBW relationship (S3 Fig). Similar but weaker trends were observed when SGA was used as the outcome among the studies with ultrasound data, but low MUAC or low BMI were significantly associated with an increased risk of PTB (S5 Table).
Interaction and EMM
The joint aRR for both malaria infection at enrollment and low MUAC was 2.13 (95% CI: 1.21, 3.73; τ2 = 0.25 [95% CI: 0.00, 1.82]; 95% PEI: 0.80, 5.67), and the mean BW difference was −163 g (95% CI: −253, −75; τ2 = 6,995 [95% CI: 0, 58,414]; 95% PEI: −328, 0). The multiplicative interaction term for LBW was 1.30 (95% CI: 0.62, 2.72; τ2 = 0.37 [95% CI: 0.00, 3.97]; 95% PEI: 0.39, 4.31), the additive interaction term for LBW was −0.01 (95% CI: −0.09, 0.08; τ2 = 0.003 [95% CI: 0.00, 0.04]; 95% PEI: −0.11, 0.09), and the additive interaction term for mean BW difference was 38 g (95% CI: −90, 166; τ2 = 17,198 [95% CI: 0, 120,165]; 95% PEI: −219, 295). Sensitivity analyses that varied the definitions of malaria, malnutrition, outcome, and analytic approach largely did not qualitatively alter the results; however, restriction to adolescent women did suggest potential multiplicative and additive interaction between low MUAC and malaria infection at enrollment among this subgroup (product term 2.49 [95% CI: 0.88, 7.02]; additive interaction term 0.08 [95% CI: −0.07, 0.22]) (S6 Table). Additionally, meta-regression indicated apparent multiplicative interaction and slight additive interaction between MUAC and malaria infection at enrollment among studies conducted in Africa (multiplicative interaction term, 2.47 [95% CI: 1.12, 5.42]; additive interaction contrast, 0.06 [95% CI: −0.05, 0.17] S4 Fig), but this interaction was not seen when assessing malaria infection at delivery or BMI or when accounting for multiple comparisons with a Bonferroni correction (99% CI: 0.88, 6.95). In EMM analyses, the aRR for the effect of malaria infection at enrollment on LBW among low MUAC women was 1.32 (95% CI: 0.66, 2.63; τ2 = 0.43 [95% CI: 0.00, 3.40]; 95% PEI: 0.36, 4.79), compared to 0.98 (95% CI: 0.74, 1.29; τ2 = 0 [95% CI: 0.00, 0.32]) among well-nourished women.
The joint aRR for both malaria infection at delivery and low MUAC was 2.16 (95% CI: 1.25, 3.74; τ2 = 0.23 [95% CI: 0.00, 1.61]; 95% PEI: 0.84, 5.55), and the mean BW difference was −196 g (95% CI: −301, −92; τ2 = 10,904 [95% CI: 0, 86,721]; 95% PEI: −401, 8). The multiplicative interaction term for LBW was 0.82 (95% CI: 0.50, 1.33; τ2 = 0 [95% CI: 0.00, 3.79]), the additive interaction term for LBW was −0.01 (95% CI: −0.10, 0.07; τ2 = 0 [95% CI: 0.00, 0.06]), and the additive interaction term for mean BW difference was −49 g (95% CI: −190, 93; τ2 = 20,087 [95% CI: 0, 154,675]; 95% PEI: −326, 229).
Discussion
Using the large M3 initiative dataset, we found that pregnant women who were both infected with malaria and malnourished were at greater risk of LBW and reduced mean BW compared to their uninfected, well-nourished counterparts, but there was overall no convincing evidence of synergism, i.e., excess risk due to interaction. This finding was consistent for both time points of malaria diagnosis (at enrollment and delivery) and both definitions of malnutrition (MUAC and BMI). This suggests that malaria infection and malnutrition largely act independently to influence fetal growth and gestational length.
A 2004 review estimated that women infected with placental malaria were twice as likely to have a LBW infant [51]. Our findings are broadly consistent with this review, although with weaker effects on LBW (overall aRR for malaria infection at delivery: 1.32 [95% CI: 1.08, 1.62], aRR restricted to African studies: 1.55 [95% CI: 1.29, 1.85]), possibly reflecting increased access to preventive strategies and fewer chronic infections [3,4]. In support of this hypothesis, the effect of malaria infection on LBW appears lower in women who received more doses of IPTp. The effects of malaria infection at enrollment on LBW were weaker than at delivery, contradicting the theory that malaria infection earlier in pregnancy is more disruptive to placental function [2]. This weaker effect at enrollment could either suggest that antimalarial treatment, provided in most studies, cleared infection and allowed catch-up growth or that infection at delivery represents more severe infections that were not cleared despite medications. Both malaria infection at enrollment and delivery were associated with a reduction in BW of around 55 grams, which has been found in other studies [52].
Our data are consistent with a 2011 meta-analysis, which estimated that underweight women had increased risk of LBW (aRR: 1.64 [95% CI: 1.38, 1.94]), although studies included in that meta-analysis used different definitions for underweight [53]. In our study, using consistent cutoffs of malnutrition across studies, both low MUAC (aRR 1.60 [95% CI: 1.36, 1.87]) and low BMI (aRR 1.49 [95% CI: 1.26, 1.76]) increased the risk of LBW. This information is consistent with other evidence that adequate maternal nutrition is integral for fetal growth [5].
Prior literature on the interaction between malaria infection and malnutrition is sparse. Two studies in the DRC and Kenya showed that the association between malaria infection and reduced fetal growth was greatest among malnourished women [10,11]. In a third study in Benin, the effect of malaria infection on fetal growth velocity was greatest among women with low anthropometric status, but there was no modification by maternal nutrition on the effect of malaria infection on BW z-scores. A fourth study in PNG found that the effect of histology-defined placental malaria infection on LBW was higher among women with a low BMI, but that study found that malnutrition did not modify the association between peripheral blood malaria infection parasitemia and SGA [9]. The Benin, Congo, and PNG studies were included in the present analysis, but our analytic approach differed from the original publications in the assessment of both interaction and modification. Unlike these prior studies, our pooled results suggest that there is a negligible impact of maternal anthropometry on the relationship between malaria infection and LBW and further indicate that there is no evidence of excess risk of LBW due to interaction (i.e., synergism). There was some indication of multiplicative and additive interaction between low MUAC and malaria infection at enrollment among adolescent women; however, these estimates were very imprecise and were only pooled across 4 studies that enrolled enough adolescent women to assess this subgroup. Adolescent women are recognized to be at high risk of adverse pregnancy outcomes [54], and tailored antenatal care programs addressing malaria, nutrition, and other health issues should be considered for this group. In an a priori sensitivity analysis restricted to African studies, there was apparent interaction between malaria infection at enrollment and MUAC, which is consistent with the prior publications. Regional differences could be due to genetics, low MUAC, or anemia prevalence; however, these subregion effects were not statistically significant when properly accounting for multiple comparisons and were absent when using other definitions of malaria (i.e., at delivery) or malnutrition (i.e., BMI). Additionally, the additive interaction, which has been argued to be the more relevant measure for public health impact [55], was only slightly elevated among the African studies. Notably, only 183 women (2%) were jointly infected and malnourished (low MUAC). Thus, even if there is a multiplicative interaction between malaria infection and MUAC among African women or among adolescent women, the proportion of women implicated is small, and does not indicate a large public health burden. However, even in the absence of strong interaction between malaria infection and malnutrition on LBW, we emphasize that interventions on both malaria infection and malnutrition are warranted given their independent effects.
This work had several strengths and limitations. We substantially increased the number of women in whom the hypothesized interaction between malaria infection, malnutrition, and LBW was investigated; notably, the number of pregnant women from Africa was almost 10 times more than all prior studies. Analyzed studies were performed in a variety of settings, increasing the generalizability of these results. Furthermore, availability of individual-level data enabled us to harmonize definitions and minimize heterogeneity. Our work is strengthened by providing results for SGA and PTB as secondary outcomes, which showed findings consistent with LBW. However, we were only able to assess SGA and PTB among a subset of nine of the 13 studies with available ultrasound-dated gestational age. There is no alternative satisfactory dating tool to ultrasound in later pregnancy, thus we used all ultrasound data provided regardless of gestation. Some women were enrolled after 24 weeks gestation (S2 Table), reducing the accuracy of ultrasound among these pregnancies and potentially underestimating gestational age in some SGA babies. Missing data were imputed using multivariate normal multiple imputation, and while not all variables followed a normal distribution (e.g., the binary variable LBW), simulation studies have shown that multivariate normal multiple imputation provides less biased estimates than complete-case analysis even when imputing binary or ordinal variables [56]. We were obliged to pool malaria diagnostics of varying sensitivity and specificity, and we were limited to 2 cross-sectional assessments of malaria infection. Nevertheless, sensitivity analyses that evaluated alternative definitions of malaria, or incorporated repeat diagnostics during pregnancy, were consistent with the main results. Additionally, there may be selection bias due to excluding pregnancy losses. There were only 116 (3%) pregnancy losses in 4 studies (N = 4,571) in the M3 initiative that collected these data, but this is almost certainly an underestimate, since many studies enrolled women after the first trimester. We were obliged to extrapolate prepregnancy BMI using gestational age and BMI at enrollment. Additionally, the M3 initiative represents a convenience sample of available and eligible studies identified through the MiPc and not an exhaustive aggregation of all existing studies available to assess interactions between malaria and malnutrition on LBW. This could potentially lead to selection bias if selection of studies were associated with the effect estimates in that study; however, we did not observe any qualitative differences between studies providing individual participant data and those studies not included in the meta-analysis (S3 Table). Furthermore, women enrolled in studies were likely healthier and received better antenatal care than the general population; the effects of malaria and malnutrition in reality might well be greater than were observed within these research settings. The risk of bias assessment identified 10 studies as being at a higher risk of bias, primarily due to BW not being measured with an electronic scale within 24 hours of delivery. Finally, we cannot discount possible unmeasured confounding, particularly by helminth infections, sexually transmitted infections, environmental pollutants, or micronutrient deficiencies; however, it is important to note that because neither malnutrition nor malaria could be randomized, large-scale, multisite cohort analyses such as this one are necessarily the gold standard for addressing these scientific questions. Future studies may wish to assess joint effects of malaria with other nutritional indicators (e.g., height, obesity, anemia, other micronutrients). Additionally, future studies may wish to further investigate possible interactions between malaria infection and malnutrition on risk of LBW in adolescent mothers.
In summary, our findings suggest that women who are both infected with malaria and malnourished are at greater risk of LBW than their uninfected, well-nourished counterparts but that there is no conclusive evidence of synergistic interaction between the 2. Rather, we propose that malaria infection and malnutrition act independently to disrupt fetal growth and that malnutrition in particular has a strong effect on LBW. Of all 14,633 pregnancies, 35% were affected by malaria infection and/or malnutrition, illustrating the high burden of at-risk pregnancies in LMICs. Malaria infection and malnutrition represent 2 established and modifiable causes of LBW that should both be addressed to optimize pregnancy outcomes in LMIC.
Supporting Information
Zdroje
1. WHO | Global Nutrition Targets 2025: Low birth weight policy brief [Internet]. WHO. [cited 2015 Aug 17]. http://www.who.int/nutrition/publications/globaltargets2025_policybrief_lbw/en/
2. Umbers AJ, Aitken EH, Rogerson SJ. Malaria in pregnancy: small babies, big problem. Trends Parasitol. 2011 Apr;27(4):168–75. doi: 10.1016/j.pt.2011.01.007 21377424
3. Desai M, ter Kuile FO, Nosten F, McGready R, Asamoa K, Brabin B, et al. Epidemiology and burden of malaria in pregnancy. Lancet Infect Dis. 2007 Feb;7(2):93–104. doi: 10.1016/S1473-3099(07)70021-X 17251080
4. Dellicour S, Tatem AJ, Guerra CA, Snow RW, ter Kuile FO. Quantifying the Number of Pregnancies at Risk of Malaria in 2007: A Demographic Study. PLoS Med. 2010 Jan 26;7(1):e1000221. doi: 10.1371/journal.pmed.1000221 20126256
5. Black RE, Victora CG, Walker SP, Bhutta ZA, Christian P, de Onis M, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. The Lancet. 2013 Aug;382(9890):427–51.
6. Lartey A. Maternal and child nutrition in Sub-Saharan Africa: challenges and interventions. Proc Nutr Soc. 2008 Feb;67(1):105–8. doi: 10.1017/S0029665108006083 18234138
7. Ververs M, Antierens A, Sackl A, Staderini N, Captier V. Which Anthropometric Indicators Identify a Pregnant Woman as Acutely Malnourished and Predict Adverse Birth Outcomes in the Humanitarian Context? PLoS Curr. 2013 Jun 7;5.
8. Unger HW, Ashorn P, Cates JE, Dewey KG, Rogerson SJ. Undernutrition and malaria in pregnancy—a dangerous dyad? BMC Med. 2016;14(1):142. doi: 10.1186/s12916-016-0695-2 27645498
9. Unger HW, Ome-Kaius M, Karl S, Singirok D, Siba P, Walker J, et al. Factors associated with ultrasound-aided detection of suboptimal fetal growth in a malaria-endemic area in Papua New Guinea. BMC Pregnancy Childbirth. 2015 Apr 3;15(1):83.
10. McClure EM, Meshnick SR, Lazebnik N, Mungai P, King CL, Hudgens M, et al. A cohort study of Plasmodium falciparum malaria in pregnancy and associations with uteroplacental blood flow and fetal anthropometrics in Kenya. Int J Gynaecol Obstet. 2014 Jul;126(1):78–82. doi: 10.1016/j.ijgo.2014.01.016 24792408
11. Landis SH, Lokomba V, Ananth CV, Atibu J, Ryder RW, Hartmann KE, et al. Impact of maternal malaria and under-nutrition on intrauterine growth restriction: a prospective ultrasound study in Democratic Republic of Congo. Epidemiol Infect. 2009 Feb;137(2):294–304. doi: 10.1017/S0950268808000915 18588723
12. Briand V, Saal J, Ghafari C, Huynh B-T, Fievet N, Schmiegelow C, et al. Fetal Growth Restriction Is Associated With Malaria in Pregnancy: A Prospective Longitudinal Study in Benin. J Infect Dis. 2016 Aug 1;214(3):417–25. doi: 10.1093/infdis/jiw158 27389349
13. van Eijk AM, Ayisi JG, Slutsker L, Ter Kuile FO, Rosen DH, Otieno JA, et al. Effect of haematinic supplementation and malaria prevention on maternal anaemia and malaria in western Kenya. Trop Med Int Health. 2007 Mar;12(3):342–52. doi: 10.1111/j.1365-3156.2006.01787.x 17313505
14. Madanitsa M, Kalilani L, Mwapasa V, van Eijk AM, Khairallah C, Ali D, et al. Scheduled Intermittent Screening with Rapid Diagnostic Tests and Treatment with Dihydroartemisinin-Piperaquine versus Intermittent Preventive Therapy with Sulfadoxine-Pyrimethamine for Malaria in Pregnancy in Malawi: An Open-Label Randomized Controlled Trial. PLoS Med. 2016 Sep;13(9):e1002124. doi: 10.1371/journal.pmed.1002124 27622558
15. Desai M, Gutman J, L’lanziva A, Otieno K, Juma E, Kariuki S, et al. Intermittent screening and treatment or intermittent preventive treatment with dihydroartemisinin-piperaquine versus intermittent preventive treatment with sulfadoxine-pyrimethamine for the control of malaria during pregnancy in western Kenya: an open-label, three-group, randomised controlled superiority trial. Lancet. 2015 Sep 28;
16. Luntamo M, Kulmala T, Mbewe B, Cheung YB, Maleta K, Ashorn P. Effect of repeated treatment of pregnant women with sulfadoxine-pyrimethamine and azithromycin on preterm delivery in Malawi: a randomized controlled trial. Am J Trop Med Hyg. 2010 Dec;83(6):1212–20. doi: 10.4269/ajtmh.2010.10-0264 21118924
17. Adu-Afarwuah S, Lartey A, Okronipa H, Ashorn P, Zeilani M, Peerson JM, et al. Lipid-based nutrient supplement increases the birth size of infants of primiparous women in Ghana. Am J Clin Nutr. 2015 Apr;101(4):835–46. doi: 10.3945/ajcn.114.091546 25833980
18. Valea I, Tinto H, Drabo MK, Huybregts L, Sorgho H, Ouedraogo J-B, et al. An analysis of timing and frequency of malaria infection during pregnancy in relation to the risk of low birth weight, anaemia and perinatal mortality in Burkina Faso. Malar J. 2012;11:71. doi: 10.1186/1475-2875-11-71 22433778
19. Huynh B-T, Fievet N, Gbaguidi G, Borgella S, Mévo BG, Massougbodji A, et al. Malaria associated symptoms in pregnant women followed-up in Benin. Malar J. 2011 Mar 31;10(1):72.
20. Schmiegelow C, Minja D, Oesterholt M, Pehrson C, Suhrs HE, Boström S, et al. Malaria and Fetal Growth Alterations in the 3rd Trimester of Pregnancy: A Longitudinal Ultrasound Study. PLoS ONE. 2013 Jan 11;8(1).
21. Kuile FOT, Terlouw DJ, Phillips-Howard PA, Hawley WA, Friedman JF, Kariuki SK, et al. Reduction of Malaria During Pregnancy by Permethrin-Treated Bed Nets in an Area of Intense Perennial Malaria Transmission in Western Kenya. Am J Trop Med Hyg. 2003 Apr 1;68(4 suppl):50–60. 12749486
22. Dellicour S, Desai M, Aol G, Oneko M, Ouma P, Bigogo G, et al. Risks of miscarriage and inadvertent exposure to artemisinin derivatives in the first trimester of pregnancy: a prospective cohort study in western Kenya. Malar J. 2015 Nov 18;14(1):461.
23. Desai M, Gutman J, Taylor SM, Wiegand RE, Khairallah C, Kayentao K, et al. Impact of Sulfadoxine-Pyrimethamine Resistance on Effectiveness of Intermittent Preventive Therapy for Malaria in Pregnancy at Clearing Infections and Preventing Low Birth Weight. Clin Infect Dis. 2016 Feb 1;62(3):323–33. doi: 10.1093/cid/civ881 26486699
24. Stanisic DI, Moore KA, Baiwog F, Ura A, Clapham C, King CL, et al. Risk factors for malaria and adverse birth outcomes in a prospective cohort of pregnant women resident in a high malaria transmission area of Papua New Guinea. Trans R Soc Trop Med Hyg. 2015 May 1;109(5):313–24. doi: 10.1093/trstmh/trv019 25758854
25. Unger HW, Cates JE, Gutman J, Briand V, Fievet N, Valea I, et al. Maternal Malaria and Malnutrition (M3) initiative, a pooled birth cohort of 13 pregnancy studies in Africa and the Western Pacific. BMJ Open. 2016 Dec 21;6(12):e012697. doi: 10.1136/bmjopen-2016-012697 28003287
26. Greenwood AM, Armstrong JR, Byass P, Snow RW, Greenwood BM. Malaria chemoprophylaxis, birth weight and child survival. Trans R Soc Trop Med Hyg. 1992 Oct;86(5):483–5. 1475810
27. Villar J, Ismail LC, Victora CG, Ohuma EO, Bertino E, Altman DG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. The Lancet. 2014 Sep;384(9946):857–68.
28. Kattenberg JH, Ochodo EA, Boer KR, Schallig HD, Mens PF, Leeflang MM. Systematic review and meta-analysis: rapid diagnostic tests versus placental histology, microscopy and PCR for malaria in pregnant women. Malar J. 2011 Oct 28;10(1):321.
29. Cottrell G, Moussiliou A, Luty AJF, Cot M, Fievet N, Massougbodji A, et al. Submicroscopic Plasmodium falciparum Infections Are Associated With Maternal Anemia, Premature Births, and Low Birth Weight. Clin Infect Dis Off Publ Infect Dis Soc Am. 2015 May 15;60(10):1481–8.
30. Kelly A, Kevany J, de Onis M, Shah PM. A WHO Collaborative Study of Maternal Anthropometry and Pregnancy Outcomes. Int J Gynaecol Obstet Off Organ Int Fed Gynaecol Obstet. 1996 Jun;53(3):219–33.
31. VanderWeele TJ, Knol M. A Tutorial on Interaction. Epidemiol Methods. 2014;3(1):33–72.
32. Wells G, Shea B, O’Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa: Ottawa Hospital Research Institute. 2014 [cited 2017 May 16]; http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
33. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. J Epidemiol Community Health. 1998 Jun;52(6):377–84. 9764259
34. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of Observational Studies in Epidemiology: A Proposal for Reporting. JAMA. 2000 Apr 19;283(15):2008–12. 10789670
35. VanderWeele TJ. On the distinction between interaction and effect modification. Epidemiol Camb Mass. 2009 Nov;20(6):863–71.
36. Stewart GB, Altman DG, Askie LM, Duley L, Simmonds MC, Stewart LA. Statistical analysis of individual participant data meta-analyses: a comparison of methods and recommendations for practice. PLoS ONE. 2012;7(10):e46042. doi: 10.1371/journal.pone.0046042 23056232
37. Simmonds MC, Higgins JPT, Stewart LA, Tierney JF, Clarke MJ, Thompson SG. Meta-analysis of individual patient data from randomized trials: a review of methods used in practice. Clin Trials Lond Engl. 2005;2(3):209–17.
38. Thomas D, Radji S, Benedetti A. Systematic review of methods for individual patient data meta- analysis with binary outcomes. BMC Med Res Methodol. 2014 Jun 19;14(1):79.
39. Greenland S, Pearl J, Robins JM. Causal diagrams for epidemiologic research. Epidemiol Camb Mass. 1999 Jan;10(1):37–48.
40. Schafer JL. Imputation of missing covariates under a multivariate linear mixed model. Dept. of Statistics, The Pennsylvania State University; Report No.: 97–04.
41. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986 Sep;7(3):177–88. 3802833
42. González R, Mombo-Ngoma G, Ouédraogo S, Kakolwa MA, Abdulla S, Accrombessi M, et al. Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Negative Women: A Multicentre Randomized Controlled Trial. PLoS Med. 2014 Sep 23;11(9):e1001733. doi: 10.1371/journal.pmed.1001733 25247709
43. González R, Desai M, Macete E, Ouma P, Kakolwa MA, Abdulla S, et al. Intermittent Preventive Treatment of Malaria in Pregnancy with Mefloquine in HIV-Infected Women Receiving Cotrimoxazole Prophylaxis: A Multicenter Randomized Placebo-Controlled Trial. PLoS Med. 2014 Sep 23;11(9):e1001735. doi: 10.1371/journal.pmed.1001735 25247995
44. Ashorn P, Alho L, Ashorn U, Cheung YB, Dewey KG, Harjunmaa U, et al. The impact of lipid-based nutrient supplement provision to pregnant women on newborn size in rural Malawi: a randomized controlled trial. Am J Clin Nutr. 2015 Feb 1;101(2):387–97. doi: 10.3945/ajcn.114.088617 25646337
45. van den Broek NR, White SA, Goodall M, Ntonya C, Kayira E, Kafulafula G, et al. The APPLe Study: A Randomized, Community-Based, Placebo-Controlled Trial of Azithromycin for the Prevention of Preterm Birth, with Meta-Analysis. PLoS Med. 2009 Dec 1;6(12):e1000191. doi: 10.1371/journal.pmed.1000191 19956761
46. Mwangi MN, Roth JM, Smit MR, Trijsburg L, Mwangi AM, Demir AY, et al. Effect of Daily Antenatal Iron Supplementation on Plasmodium Infection in Kenyan Women: A Randomized Clinical Trial. JAMA. 2015 Sep 8;314(10):1009–20. doi: 10.1001/jama.2015.9496 26348751
47. Toko EN, Sumba OP, Daud II, Ogolla S, Majiwa M, Krisher JT, et al. Maternal Vitamin D Status and Adverse Birth Outcomes in Children from Rural Western Kenya. Nutrients. 2016 Dec 7;8(12).
48. Kakuru A, Jagannathan P, Muhindo MK, Natureeba P, Awori P, Nakalembe M, et al. Dihydroartemisinin-Piperaquine for the Prevention of Malaria in Pregnancy. N Engl J Med. 2016 Mar 10;374(10):928–39. doi: 10.1056/NEJMoa1509150 26962728
49. Ouédraogo S, Koura GK, Accrombessi MMK, Bodeau-Livinec F, Massougbodji A, Cot M. Maternal Anemia at First Antenatal Visit: Prevalence and Risk Factors in a Malaria-Endemic Area in Benin. Am J Trop Med Hyg. 2012 Sep 5;87(3):418–24. doi: 10.4269/ajtmh.2012.11-0706 22826498
50. Briand V, Denoeud L, Massougbodji A, Cot M. Efficacy of Intermittent Preventive Treatment versus Chloroquine Prophylaxis to Prevent Malaria during Pregnancy in Benin. J Infect Dis. 2008 Aug 15;198(4):594–601. doi: 10.1086/590114 18598190
51. Guyatt HL, Snow RW. Impact of Malaria during Pregnancy on Low Birth Weight in Sub-Saharan Africa. Clin Microbiol Rev. 2004 Oct;17(4):760–9. doi: 10.1128/CMR.17.4.760-769.2004 15489346
52. Rijken MJ, De Livera AM, Lee SJ, Boel ME, Rungwilailaekhiri S, Wiladphaingern J, et al. Quantifying Low Birth Weight, Preterm Birth and Small-for-Gestational-Age Effects of Malaria in Pregnancy: A Population Cohort Study. PLoS ONE [Internet]. 2014 Jul 1 [cited 2016 Jul 7];9(7). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4077658/
53. Han Z, Mulla S, Beyene J, Liao G, McDonald SD. Maternal underweight and the risk of preterm birth and low birth weight: a systematic review and meta-analyses. Int J Epidemiol. 2011 Feb 1;40(1):65–101. doi: 10.1093/ije/dyq195 21097954
54. Mombo-Ngoma G, Mackanga JR, González R, Ouedraogo S, Kakolwa MA, Manego RZ, et al. Young adolescent girls are at high risk for adverse pregnancy outcomes in sub-Saharan Africa: an observational multicountry study. BMJ Open [Internet]. 2016 Jun 29;6(6). Available from: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4932321/
55. VanderWeele TJ, Vansteelandt S, Robins JM. Marginal Structural Models for Sufficient Cause Interactions. Am J Epidemiol. 2010 Feb 15;171(4):506–14. doi: 10.1093/aje/kwp396 20067916
56. Lee KJ, Carlin JB. Multiple imputation for missing data: fully conditional specification versus multivariate normal imputation. Am J Epidemiol. 2010 Mar 1;171(5):624–32. doi: 10.1093/aje/kwp425 20106935
Štítky
Interné lekárstvoČlánok vyšiel v časopise
PLOS Medicine
2017 Číslo 8
- Statinová intolerance
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Metamizol v liečbe pooperačnej bolesti u detí do 6 rokov veku
- Co dělat při intoleranci statinů?
Najčítanejšie v tomto čísle
- Childhood adiposity and risk of type 1 diabetes: A Mendelian randomization study
- Benefits and safety of gabapentinoids in chronic low back pain: A systematic review and meta-analysis of randomized controlled trials
- Lay worker-administered behavioral treatments for psychological distress in resource-limited settings: Time to move from evidence to practice?
- Evaluating the impact of Affordable Care Act repeal on America's opioid epidemic